Hidalgo-Mazzei Diego, Mantingh Tim, Pérez de Mendiola Xavier, Samalin Ludovic, Undurraga Juan, Strejilevich Sergio, Severus Emanuel, Bauer Michael, González-Pinto Ana, Nolen Willem A, Young Allan H, Vieta Eduard
Bipolar and depressive disorders unit, Department of Psychiatry and Psychology, Hospital Clínic, IDIBAPS, University of Barcelona, 170 Villarroel St, 08036, Barcelona, Spain.
Departament de Medicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), C. Casanova, 143, 08036, Barcelona, Spain.
Int J Bipolar Disord. 2023 May 27;11(1):20. doi: 10.1186/s40345-023-00301-y.
Lithium has long been considered the gold-standard pharmacological treatment for the maintenance treatment of bipolar disorders (BD) which is supported by a wide body of evidence. Prior research has shown a steady decline in lithium prescriptions during the last two decades. We aim to identify potential factors explaining this decline across the world with an anonymous worldwide survey developed by the International Society for Bipolar Disorders (ISBD) Task Force "Role of Lithium in Bipolar Disorders" and distributed by diverse academic and professional international channels.
A total of 886 responses were received of which 606 completed the entire questionnaire while 206 completed it partially. Respondents were from 43 different countries comprising all continents. Lithium was the most preferred treatment option for the maintenance of BD patients (59%). The most relevant clinical circumstances in which lithium was the preferred option were in patients with BD I (53%), a family history of response (18%), and a prior response during acute treatment (17%). In contrast, Lithium was not the preferred option in case of patients´ negative beliefs and/or attitudes towards lithium (13%), acute side-effects or tolerability problems (10%) and intoxication risk (8%). Clinicians were less likely to prefer lithium as a first option in BD maintenance phase when practising in developing economy countries [X2 (1, N = 430) = 9465, p = 0.002) ] and private sectors [X2 (1, N = 434) = 8191, p = 0.004)].
Clinicians' preferences and attitudes towards the use of lithium in the maintenance treatment of bipolar disorders appear to be affected by both the patients' beliefs and the professional contexts where clinicians provide their services. More research involving patients is needed for identifying their attitudes toward lithium and factors affecting its use, particularly in developing economies.
长期以来,锂盐一直被视为双相情感障碍(BD)维持治疗的金标准药物治疗方法,这一观点有大量证据支持。先前的研究表明,在过去二十年中,锂盐处方量呈稳步下降趋势。我们旨在通过国际双相情感障碍协会(ISBD)“锂盐在双相情感障碍中的作用”特别工作组开发并通过各种国际学术和专业渠道分发的一项匿名全球调查,确定全球范围内导致这种下降的潜在因素。
共收到886份回复,其中606份完成了全部问卷,206份部分完成。受访者来自包括各大洲的43个不同国家。锂盐是BD患者维持治疗的首选治疗方案(59%)。锂盐成为首选方案的最相关临床情况是BD I型患者(53%)、有反应家族史的患者(18%)以及急性治疗期间有过反应的患者(17%)。相比之下,在患者对锂盐有负面信念和/或态度(13%)、急性副作用或耐受性问题(10%)以及中毒风险(8%)的情况下,锂盐不是首选方案。在发展中经济体国家执业时[X2(1,N = 430)= 9465,p = 0.002]以及在私营部门执业时[X2(1,N = 434)= 8191,p = 0.004],临床医生在BD维持期将锂盐作为首选方案的可能性较小。
临床医生在双相情感障碍维持治疗中对锂盐使用的偏好和态度似乎受到患者信念以及临床医生提供服务的专业背景的影响。需要开展更多涉及患者的研究,以确定他们对锂盐的态度以及影响其使用的因素,特别是在发展中经济体中。